Trend in approval of targeted biologics in the last two decades
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.
| Päätekijä: | |
|---|---|
| Muut tekijät: | |
| Aineistotyyppi: | Opinnäyte |
| Kieli: | English |
| Julkaistu: |
Brac University
2024
|
| Aiheet: | |
| Linkit: | http://hdl.handle.net/10361/24296 |
| id |
10361-24296 |
|---|---|
| record_format |
dspace |
| spelling |
10361-242962024-10-03T21:02:28Z Trend in approval of targeted biologics in the last two decades Siddika, Khadiza Ahmed, Syeda Maliha School of Pharmacy, Brac University Molecular pathway Targeted biologics Cancer therapy FDA Biologicals. This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024. Cataloged from PDF version of thesis. Includes bibliographical references (pages 24-28). Over the past two decades, the approval of targeted biologics has significantly transformed therapeutic landscapes, particularly for chronic diseases like cancer. These therapies, specifically target diseases' molecular pathways, offer enhanced efficacy and fewer side effects than traditional chemotherapy. This review assesses the trends in regulatory approval by the FDA, noting a surge in approvals for targeted biologics over the last two decades. The shift towards targeted biologics promises more precise management of the complexities of cancer. This review compiles the FDA's trends in approving targeted biologics for cancer from January 2000 to December 2022 based on product class, rate of approvals, biological target, and disease site. Despite the advancements in targeted cancer therapies, there is a need to comprehensively understand the evolving trends in FDA approvals during the twenty-first century. This study investigates the approval patterns, identifies influencing factors, and provides insights that can contribute to optimizing the development and processes of targeted biologics. This may serve as a good insight for researchers in academia and industry to identify fields in which cancer research and funding may be mostly directed. Khadiza Siddika B. Pharmacy 2024-10-03T05:41:43Z 2024-10-03T05:41:43Z ©2024 2024-04 Thesis ID 19346027 http://hdl.handle.net/10361/24296 en Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. 33 pages application/pdf Brac University |
| institution |
Brac University |
| collection |
Institutional Repository |
| language |
English |
| topic |
Molecular pathway Targeted biologics Cancer therapy FDA Biologicals. |
| spellingShingle |
Molecular pathway Targeted biologics Cancer therapy FDA Biologicals. Siddika, Khadiza Trend in approval of targeted biologics in the last two decades |
| description |
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024. |
| author2 |
Ahmed, Syeda Maliha |
| author_facet |
Ahmed, Syeda Maliha Siddika, Khadiza |
| format |
Thesis |
| author |
Siddika, Khadiza |
| author_sort |
Siddika, Khadiza |
| title |
Trend in approval of targeted biologics in the last two decades |
| title_short |
Trend in approval of targeted biologics in the last two decades |
| title_full |
Trend in approval of targeted biologics in the last two decades |
| title_fullStr |
Trend in approval of targeted biologics in the last two decades |
| title_full_unstemmed |
Trend in approval of targeted biologics in the last two decades |
| title_sort |
trend in approval of targeted biologics in the last two decades |
| publisher |
Brac University |
| publishDate |
2024 |
| url |
http://hdl.handle.net/10361/24296 |
| work_keys_str_mv |
AT siddikakhadiza trendinapprovaloftargetedbiologicsinthelasttwodecades |
| _version_ |
1814308176581885952 |